Human TRAIL R2/TNFRSF10B Antibody | R&D Systems MAB6311 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human TRAIL R2/TNFRSF10B Antibody

catalog :

MAB6311

quantity :

500 ug (also 25 ug)

price :

559 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

71908

reactivity :

human, mouse

application :

immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

more info or order :

R&D Systems product webpage

citations: 26

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human	Labovsky V, Martinez L, Davies K, Garcia Rivello H, Calcagno M, Matas A, et al. Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells. Clin Breast Cancer. 2015;15:e13-21 pubmed publisher
flow cytometry; human	Stenqvist A, Nagaeva O, Baranov V, Mincheva Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J Immunol. 2013;191:5515-23 pubmed publisher
flow cytometry; mouse	Neumann S, Bidon T, Branschädel M, Krippner Heidenreich A, Scheurich P, Doszczak M. The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. PLoS ONE. 2012;7:e42526 pubmed publisher
flow cytometry; human	Moniri M, Sun X, Rayat J, Dai D, Ao Z, He Z, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19:652-8 pubmed publisher
flow cytometry; human; 5 ug/ml	Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed publisher
flow cytometry; human	Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J Cell Physiol. 2010;222:357-64 pubmed publisher
flow cytometry; human	Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114:3854-63 pubmed publisher
flow cytometry; human	Seal S, Hockenbery D, Spaulding E, Kiem H, Abbassi N, Deeg H. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol. 2008;36:1660-72 pubmed publisher
flow cytometry; human	Toscano F, Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle J, et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene. 2008;27:4161-71 pubmed publisher
flow cytometry; human	Weinmann L, Wischhusen J, Demma M, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008;15:718-29 pubmed publisher
flow cytometry; human	Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008;104:595-605 pubmed
	Krishna Moorthy N, Seifert O, Eisler S, Weirich S, Kontermann R, Rehm M, et al. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. Molecules. 2021;26: pubmed publisher
	Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, et al. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death Dis. 2021;12:647 pubmed publisher
	Yoo J, Bae S, Seo J, Jeon I, Vadevoo S, Kim S, et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci Rep. 2020;10:19997 pubmed publisher
	Bachsais M, Salti S, Zaoui K, Hassan G, Aoudjit F, Mourad W. CD154 inhibits death of T cells via a Cis interaction with the α5β1 integrin. PLoS ONE. 2020;15:e0235753 pubmed publisher
	Stöhr D, Schmid J, Beigl T, Mack A, Maichl D, Cao K, et al. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death Differ. 2020;: pubmed publisher
	Lee S, Hyun S, Kim H, Kang C, Kim S. Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL. Oncol Res. 2016;24:495-509 pubmed publisher
	Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A. Interferon-Î² inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol. 2014;45:1837-46 pubmed publisher
	Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem. 2014;289:16576-87 pubmed publisher
	Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
	Suzuki Karasaki M, Ochiai T, Suzuki Karasaki Y. Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells. Int J Oncol. 2014;44:616-28 pubmed publisher
	Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. PLoS ONE. 2013;8:e58855 pubmed publisher
	Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, et al. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis. 2012;3:e295 pubmed publisher
	Shankar S, Chen Q, Ganapathy S, Singh K, Srivastava R. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther. 2008;7:2328-38 pubmed publisher
	Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy P, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007;204:667-80 pubmed
	Singh T, Shankar S, Srivastava R. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24:4609-23 pubmed

product information

master code :

MAB6311

SKU :

MAB6311

product name :

Human TRAIL R2/TNFRSF10B Antibody

unit size :

500 ug (also 25 ug)

description :

The Human TRAIL R2/TNFRSF10B Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR2/TNFRSF10B. This antibody reacts with human,mouse,rat. The Human TRAIL R2/TNFRSF10B Antibody has been validated for the following applications: Immunocytochemistry,Flow Cytometry,Immunohistochemistry-Paraffin,CyTOF-ready.

target :

TRAIL R2/TNFRSF10B

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Monoclonal

clone :

71908

conjugate :

Unconjugated

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B, Ile56-Glu182, Accession # O14763

isotype :

IgG2b

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human,Mouse,Rat

specificity :

Detects human TRAIL R2 in direct ELISAs and Western blots. In direct ELISAs, does not cross-react with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or recombinant mouse TRAIL R2.

gene symbol :

TNFRSF10B

top caption :

Detection of Human TRAILR2/TNFRSF10B by Flow Cytometry

accessionNumbers :

O14763

applications :

Immunocytochemistry,Flow Cytometry,Immunohistochemistry-Paraffin,CyTOF-ready

USD :

559 USD

alt names :

CD262, CD262 antigen, death domain containing receptor for TRAIL/Apo-2L, Death receptor 5, DR5, DR5TRICK2B, Fas-like protein, KILLER/DR5, KILLERapoptosis inducing protein TRICK2A/2B, TNF-related apoptosis-inducing ligand receptor 2, TNFRSF10B, TRAIL receptor 2, TRAILR2, TRAIL-R2apoptosis inducing receptor TRAIL-R2, TRAILR2cytotoxic TRAIL receptor-2, TRICK2, TRICK2A, TRICKB, tumor necrosis factor receptor superfamily member 10B, tumor necrosis factor receptor superfamily, member 10b, tumor necrosis factor receptor-like protein ZTNFR9, ZTNFR9

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage